Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a ...

Summer's rise in COVID-19 cases led to the approval of updated versions of vaccinations targeting recent strains for the 2024 ...

Novavax (NVX-CoV2373) is a brand-name vaccine that’s prescribed to help prevent COVID-19. As with other drugs, Novavax can cause side effects, such as pain or swelling at the injection site ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell ...

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has cut its guidance multiple times this year, and the new range is below ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year. The company now expects $650 million to $700 million in ...

The Gaithersburg biotech is preparing to turn over sales activity for its only product to its commercial partner. Novavax Inc. has made a smaller splash in the U.S. Covid-19 vaccine market than it ...

About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and ...